Ramucirumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ramucirumab: Uterine ligament adenocarcinoma
One-Sentence Summary
Ramucirumab was originally used to treat cancers including non-small cell lung carcinoma, gastric adenocarcinoma and hepatocellular carcinoma. The TxGNN model predicts it may be effective for uterine ligament adenocarcinoma, but the data compiled for this report contain no clinical trials and no publications for this indication, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Uterine ligament adenocarcinoma |
| TxGNN Prediction Score | 0.9995 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Ramucirumab is generally described as a VEGFR2 antagonist, a class of anti-angiogenic drugs. Its efficacy has been established in gastric, lung and liver cancers, and mechanistically it may be applicable to other adenocarcinomas that depend on new blood vessel growth.
The high score most likely reflects similarities the TxGNN model (deep learning) learned between the new indication and already-approved adenocarcinoma indications (gastric, lung), not biological evidence or any disease-specific data. No drug-specific data exist for this rare tumor, so the mechanistic link remains a hypothesis.
Other top-ranked predictions are mostly gynaecological adenocarcinomas, all scored about 99.94–0.9995:
- Endocervical carcinoma
- Adenoid cystic carcinoma of the cervix uteri
- Uterine ligament serous, endometrioid, clear cell and mucinous adenocarcinomas
- Signet ring cell variant cervical mucinous adenocarcinoma
- Cervical adenosquamous carcinoma, glassy cell variant
- Intestinal variant cervical mucinous adenocarcinoma
Two of these (signet ring and intestinal variants) resemble gastrointestinal adenocarcinoma histology, which may partly explain their scores. For endocervical carcinoma, another anti-VEGF drug (bevacizumab) has Phase 3 support, but that is a class-level rationale and is not evidence for ramucirumab. None of these predictions has ramucirumab-specific trials or literature in the compiled data.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02443805 | CYRAMZA | Not specified | Not specified |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (monoclonal antibody against VEGFR2), not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Drug Interactions: The interaction screening completed and returned 100 interacting drugs. The first 20 reviewed include:
- Major:
- Acetylsalicylic acid
- Deferasirox
- Ibritumomab tiuxetan
- Tositumomab and Tositumomab (I-131)
- Antithrombotic and anticoagulant agents: abciximab, alteplase, antithrombin III human, apixaban, betrixaban, bivalirudin, cangrelor, caplacizumab, cilostazol, clopidogrel, dalteparin, defibrotide
- Moderate: Dexfenfluramine, fenfluramine, sibutramine
Most major interactions involve drugs that affect clotting or platelet function, so combining them with ramucirumab warrants attention to bleeding risk. The remaining interacting drugs were not reviewed here.
For warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a very high model score (0.9995), but there are no clinical trials or publications for uterine ligament adenocarcinoma, so evidence is at the lowest level (L5). The score likely reflects similarity to approved adenocarcinoma indications rather than disease-specific data.
To proceed, the following is needed:
- Ramucirumab-specific preclinical or clinical data for this tumour, including a literature and trial registry search
- Detailed mechanism of action data
- Package insert warnings and contraindications from Health Canada, and the approved indication text for the licence
- Assessment of whether this rare tumour can realistically support a clinical study, or whether a more common gynaecological indication such as endocervical carcinoma should be prioritised
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.